Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

Investigational New Drugs ◽

10.1023/b:drug.0000026258.02846.1c ◽

2004 ◽

Vol 22 (3) ◽

pp. 315-322 ◽

Author(s):

Susan Burdette-Radoux ◽

Richard G. Tozer ◽

Reinhard C. Lohmann ◽

Ian Quirt ◽

D. Scott Ernst ◽

...

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Metastatic Malignant Melanoma ◽

Cyclin Dependent Kinase ◽

Cyclin Dependent Kinase Inhibitor

Download Full-text

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2013.10.016 ◽

2014 ◽

Vol 14 (3) ◽

pp. 169-176 ◽

Author(s):

Monica M. Mita ◽

Anil A. Joy ◽

Alain Mita ◽

Kamalesh Sankhala ◽

Ying-Ming Jou ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Advanced Breast ◽

Cyclin Dependent Kinase ◽

Cyclin Dependent Kinase Inhibitor ◽

Randomized Phase Ii

Download Full-text

Phase II Trial of Carboplatin in Patients with Metastatic Malignant Melanoma

American Journal of Clinical Oncology ◽

10.1097/00000421-199304000-00015 ◽

1993 ◽

Vol 16 (2) ◽

pp. 152-155 ◽

Author(s):

A. Chang ◽

M. Hunt ◽

D. R. Parkinson ◽

H. Hochster ◽

T. J. Smith

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Malignant Melanoma

Download Full-text

A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2015.02.021 ◽

2015 ◽

Vol 15 (7) ◽

pp. 392-397 ◽

Author(s):

Ryan D. Cassaday ◽

Andre Goy ◽

Suresh Advani ◽

Purvi Chawla ◽

Rajesh Nachankar ◽

...

Keyword(s):

Mantle Cell Lymphoma ◽

Phase Ii ◽

Multicenter Study ◽

Kinase Inhibitor ◽

Cell Lymphoma ◽

Cyclin Dependent Kinase ◽

Efficacy And Safety ◽

Cyclin Dependent Kinase Inhibitor ◽

Download Full-text

Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7558 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7558-7558 ◽

Author(s):

E. M. Hersh ◽

S. O’Day ◽

R. Gonzalez ◽

W. E. Samlowski ◽

M. S. Gordon ◽

...

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Malignant Melanoma ◽

Multicenter Phase ◽

Previously Treated

Download Full-text

Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma

Investigational New Drugs ◽

10.1007/bf00176827 ◽

1985 ◽

Vol 3 (1) ◽

pp. 67-69 ◽

Author(s):

Sarah A. Taylor ◽

Bill T. Tranum ◽

Daniel D. Von Hoff ◽

John J. Costanzi

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Malignant Melanoma

Download Full-text

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10‐06)

The Oncologist ◽

10.1634/theoncologist.2015-0161 ◽

2015 ◽

Vol 20 (11) ◽

pp. 1312-1319 ◽

Author(s):

Su Jin Lee ◽

Tae Min Kim ◽

Yu Jung Kim ◽

Kee‐Taek Jang ◽

Hyo Jin Lee ◽

...

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Malignant Melanoma ◽

Multicenter Trial ◽

Study Group ◽

Cancer Study ◽

Cancer Study Group ◽

Download Full-text

39 In vivo overexpression of the cyclin-dependent kinase inhibitor p21WAF1/C1P1 in cutaneous malignant melanoma

Journal of Dermatological Science ◽

10.1016/0923-1811(96)83606-1 ◽

1996 ◽

Vol 12 (1) ◽

pp. 89

Author(s):

M.J. Trotter ◽

L Tang ◽

V.C. Ho ◽

V.A. Tron

Keyword(s):

Malignant Melanoma ◽

Kinase Inhibitor ◽

Cutaneous Malignant Melanoma ◽

Cyclin Dependent Kinase ◽

Cyclin Dependent Kinase Inhibitor

Download Full-text

A Low Rate of Central Nervous System Progression in a Phase II Trial of Outpatient Chemobiologic Therapy With Cisplatin, Temozolomide, Interleukin-2, and Interferon Alfa 2-B for Metastatic Malignant Melanoma

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000164006.72694.1b ◽

2005 ◽

Vol 28 (5) ◽

pp. 479-484 ◽

Author(s):

Neal Ready ◽

Frederick Aronson ◽

Harold Wanebo ◽

Theresa Kennedy

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Malignant Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Interleukin 2 ◽

Metastatic Malignant Melanoma ◽

Interferon Alfa ◽

Download Full-text

A randomized phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma

Melanoma Research ◽

10.1097/00008390-200308000-00008 ◽

2003 ◽

Vol 13 (4) ◽

pp. 389-393 ◽

Author(s):

S Nicholson ◽

K Guile ◽

J John ◽

I A Clarke ◽

J Diffley ◽

...

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Interleukin 2 ◽

Metastatic Malignant Melanoma ◽

Mycobacterium Vaccae ◽

Randomized Phase Ii

Download Full-text

Phase II trial of fotemustine in patients with metastatic malignant melanoma

Investigational New Drugs ◽

10.1007/bf00873967 ◽

1994 ◽

Vol 12 (3) ◽

pp. 251-254 ◽

Author(s):

Carla I. Falkson ◽

Geoffrey Falkson ◽

Hendr� C. Falkson

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Malignant Melanoma

Download Full-text